ES2163283T3 - Composiciones farmaceuticas que contienen un inhibidor de la reductasa de aldosa y un inhibidor de la ace. - Google Patents

Composiciones farmaceuticas que contienen un inhibidor de la reductasa de aldosa y un inhibidor de la ace.

Info

Publication number
ES2163283T3
ES2163283T3 ES98932358T ES98932358T ES2163283T3 ES 2163283 T3 ES2163283 T3 ES 2163283T3 ES 98932358 T ES98932358 T ES 98932358T ES 98932358 T ES98932358 T ES 98932358T ES 2163283 T3 ES2163283 T3 ES 2163283T3
Authority
ES
Spain
Prior art keywords
inhibitor
pharmaceutical compositions
compositions containing
aldosa
ace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98932358T
Other languages
English (en)
Inventor
Frank Carey
David Patrick Tuffin
Norman Eugene Cameron
Mary Anne Cotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2163283T3 publication Critical patent/ES2163283T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una composiciones farmacéuticas que contienen un inhibidor de la reductasa de la aldosa y un inhibidor de la enzima de la conversión, y su utilización en el tratamiento de las complicaciones de la diabetes, como la neuropatía diabética, la retinopatía diabética y la nefropatía diabética.
ES98932358T 1997-07-08 1998-07-02 Composiciones farmaceuticas que contienen un inhibidor de la reductasa de aldosa y un inhibidor de la ace. Expired - Lifetime ES2163283T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9714274.9A GB9714274D0 (en) 1997-07-08 1997-07-08 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ES2163283T3 true ES2163283T3 (es) 2002-01-16

Family

ID=10815469

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98932358T Expired - Lifetime ES2163283T3 (es) 1997-07-08 1998-07-02 Composiciones farmaceuticas que contienen un inhibidor de la reductasa de aldosa y un inhibidor de la ace.

Country Status (28)

Country Link
US (1) US6337327B1 (es)
EP (1) EP0991424B1 (es)
JP (1) JP2002509540A (es)
KR (1) KR20010015551A (es)
CN (1) CN1186097C (es)
AT (1) ATE205402T1 (es)
AU (1) AU746211B2 (es)
BR (1) BR9810570A (es)
CA (1) CA2292451A1 (es)
CZ (1) CZ290276B6 (es)
DE (1) DE69801661T2 (es)
DK (1) DK0991424T3 (es)
ES (1) ES2163283T3 (es)
GB (1) GB9714274D0 (es)
HK (1) HK1028876A1 (es)
HU (1) HU224009B1 (es)
ID (1) ID24597A (es)
IL (1) IL133004A (es)
NO (1) NO20000045D0 (es)
NZ (1) NZ501165A (es)
PL (1) PL337925A1 (es)
PT (1) PT991424E (es)
RU (1) RU2216354C2 (es)
SK (1) SK122000A3 (es)
TR (1) TR199903026T2 (es)
UA (1) UA64761C2 (es)
WO (1) WO1999002189A1 (es)
ZA (1) ZA985993B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) * 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
JP2005503378A (ja) * 2001-08-06 2005-02-03 ジエノメツド・エル・エル・シー Ａｃｅの過剰に関連する疾患の治療方法及び組成物
AU2002352145A1 (en) * 2001-11-26 2003-06-10 Bayer Healthcare Ag Regulation of human aldose reductase-like protein
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
DK2771003T3 (en) 2011-10-28 2017-07-17 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease
US20150197536A1 (en) * 2012-07-28 2015-07-16 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
CN103063794B (zh) * 2012-12-24 2014-08-06 扬子江药业集团南京海陵药业有限公司 一种依帕司他片的含量检测控制方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications

Also Published As

Publication number Publication date
PL337925A1 (en) 2000-09-11
NO20000045L (no) 2000-01-06
NZ501165A (en) 2001-06-29
GB9714274D0 (en) 1997-09-10
CA2292451A1 (en) 1999-01-21
WO1999002189A1 (en) 1999-01-21
SK122000A3 (en) 2000-06-12
BR9810570A (pt) 2000-09-19
AU746211B2 (en) 2002-04-18
IL133004A0 (en) 2001-03-19
US6337327B1 (en) 2002-01-08
CN1261804A (zh) 2000-08-02
CN1186097C (zh) 2005-01-26
DE69801661T2 (de) 2002-07-04
ZA985993B (en) 1999-01-18
KR20010015551A (ko) 2001-02-26
HU224009B1 (hu) 2005-04-28
IL133004A (en) 2004-12-15
HK1028876A1 (en) 2001-03-09
EP0991424B1 (en) 2001-09-12
AU8229698A (en) 1999-02-08
UA64761C2 (uk) 2004-03-15
JP2002509540A (ja) 2002-03-26
CZ200017A3 (cs) 2000-05-17
EP0991424A1 (en) 2000-04-12
PT991424E (pt) 2002-02-28
ID24597A (id) 2000-07-27
DK0991424T3 (da) 2001-12-03
HUP0002644A2 (hu) 2000-12-28
ATE205402T1 (de) 2001-09-15
NO20000045D0 (no) 2000-01-06
CZ290276B6 (cs) 2002-06-12
RU2216354C2 (ru) 2003-11-20
TR199903026T2 (xx) 2000-04-21
DE69801661D1 (de) 2001-10-18

Similar Documents

Publication Publication Date Title
ES2163283T3 (es) Composiciones farmaceuticas que contienen un inhibidor de la reductasa de aldosa y un inhibidor de la ace.
ES2161548T3 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.
MX9602399A (es) Composicion farmaceutica.
ECSP055573A (es) COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE
BR0307960A (pt) N-aminoacetil-pirrolidina-2-carbonitrilas e seu uso como inibidores de ddp-iv
NO20044487L (no) Kombinasjon av organiske forbindelser
CR20120384A (es) Composición de farmaco conjugado
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
AR043150A1 (es) Composicion oral que contiene enzimas con estabilidad mejorada
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
BRPI0513133A (pt) composições farmacêuticas, que contêm diaminooxidase
BR0307494A (pt) Composição que contêm extrato de palha de aveia e de erva de salgueiro
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
EA200500326A1 (ru) Применение ферментированного экстракта проростков пшеницы в качестве противовоспалительного агента
DE60014960D1 (de) Alizarin-derivate als neue chromogene substrate
AR031404A1 (es) Una composicion y metodo de aplicacion
ATE474603T1 (de) Stabilisiertes leukotrien b4 (ltb4) pharmazeutikum
DE60116474D1 (de) Hcv ns2/3 fragmente und ihre verwendungen
BR0313543A (pt) 2,3-diidro-isoindol-1-onas com atividade de inibição de mao-b
GT200300022S (es) Botella.
GT200300020S (es) Botella.
PA8498601A1 (es) Composicion anticoloracion
GT200300021S (es) Botella.
DOP2003000676A (es) Formulacion farmaceutica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 991424

Country of ref document: ES